liposomal doxorubicin
Selected indexed studies
- Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization. (Int J Pharm, 2021) [PMID:33259901]
- An overview of doxorubicin formulations in cancer therapy. (J Cancer Res Ther, 2014) [PMID:25579518]
- Effectiveness of doxorubicin-based and liposomal doxorubicin chemotherapies for patients with extra-abdominal desmoid-type fibromatosis: a systematic review. (Jpn J Clin Oncol, 2020) [PMID:32700733]
_Worker-drafted node — pending editorial review._
Connections
liposomal doxorubicin is a side effect of
Sources
- An overview of doxorubicin formulations in cancer therapy. (2014) pubmed
- Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization. (2021) pubmed
- Effectiveness of doxorubicin-based and liposomal doxorubicin chemotherapies for patients with extra-abdominal desmoid-type fibromatosis: a systematic review. (2020) pubmed
- Pegylated-liposomal Doxorubicin-induced Glomerular Thrombotic Microangiopathy. (2024) pubmed
- Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review. (2021) pubmed
- Pegylated liposomal doxorubicin: a guide to its use in various malignancies. (2013) pubmed
- Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery. (2021) pubmed
- TLD: An optimized liposomal doxorubicin formulation with small vesicle size for improved anti-tumor efficacy. (2025) pubmed
- Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. (2008) pubmed
- Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice. (2017) pubmed